The company is expected to release complete financial results for the fourth quarter and full-year 2024 later in the first quarter of 2025, as stated in the press release. While the company wasn't profitable in the last twelve months, InvestingPro data indicates analysts expect profitability in the coming year, with an EPS forecast of $3.38 for 2024. For deeper insights into Pacira's financial health and growth potential, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, which covers over 1,400 US stocks with detailed analysis and actionable intelligence. While the company wasn't profitable in the last twelve months, InvestingPro data indicates analysts expect profitability in the coming year, with an EPS forecast of $3.38 for 2024. For deeper insights into Pacira's financial health and growth potential, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, which covers over 1,400 US stocks with detailed analysis and actionable intelligence. Alongside the financial update, the company has also unveiled a strategic plan targeting growth and value creation by 2030.
The company is expected to release complete financial results for the fourth quarter and full-year 2024 later in the first quarter of 2025, as stated in the press release. While the company wasn't profitable in the last twelve months, InvestingPro data indicates analysts expect profitability in the coming year, with an EPS forecast of $3.38 for 2024. For deeper insights into Pacira's financial health and growth potential, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, which covers over 1,400 US stocks with detailed analysis and actionable intelligence.
Pacira's CEO, Frank D. Lee, expressed his enthusiasm for leading the company through this transformative phase, emphasizing the aim to meet unmet patient needs in musculoskeletal pain management.
For the fourth quarter of 2024, the company highlighted net product sales of $147.7 million for EXPAREL, its flagship product, up from $143.9 million in the same period of 2023. ZILRETTA, another key product, saw fourth-quarter sales rise to $33.1 million from $28.7 million year over year. Sales of iovera°, a device for drug-free pain control, also increased slightly to $6.5 million in the fourth quarter.
Full-year sales figures for EXPAREL reached $549.0 million, while ZILRETTA and iovera° netted $118.1 million and $22.8 million, respectively. Other revenue streams, including bupivacaine liposome injectable suspension sales and royalties, contributed $11.1 million in 2024.
The company is expected to release complete financial results for the fourth quarter and full-year 2024 later in the first quarter of 2025, as stated in the press release.
In addition, Pacira announced inducement awards granted to eight new employees under the Nasdaq Listing Rule 5635(c)(4) on January 3, 2025, as an incentive for joining the company.
The information in this article is based on a press release statement from Pacira BioSciences, Inc.
In other recent news, Pacira BioSciences announced significant developments in non-opioid pain therapies and financial performance. The company secured FDA clearance for a new back pain treatment and reported promising results from its osteoarthritis gene therapy trial. Pacira's third quarter 2024 results showed an increase in EXPAREL sales to $132 million, up from $128.7 million the previous year. The non-GAAP gross margin stood at 78%, and the adjusted EBITDA was reported at $54.7 million. The company's 2024 revenue guidance was reiterated at $680 million to $705 million, with adjusted gross margins between 74% and 76%.
The recent FDA clearance for the iovera° system, which operates through cryoneurolysis, marks a significant advancement in providing a drug-free solution for long-lasting pain relief. A pilot study comparing iovera° cryoneurolysis to radiofrequency ablation (RFA) for chronic back pain highlighted the benefits of the iovera° system, with patients reporting lower pain scores and improved functional outcomes over a year.
In terms of gene therapy, the company's candidate, PCRX-201, demonstrated sustained improvements in knee pain, stiffness, and function for up to 104 weeks in patients with moderate to severe osteoarthritis of the knee. Phase 2 of the study is planned for 2025. These developments underscore Pacira's ongoing commitment to non-opioid pain therapies and patient care, despite challenges with ZILRETTA.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.